Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components
NCT04377945 is registered in ClinicalTrials.gov with Bukwang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-Controlled, Two-Part Study in Parkinson's Disease Patients With Dyskinesia to Assess the Efficacy and Safety/Tolerability of Fixed Dose Combinations of JM-010 and Its Individual Components
- Lead sponsor
- Bukwang Pharmaceutical
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- April 28, 2021
- Completion date
- February 14, 2024
- Enrollment
- 41 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.